HONG KONG, Feb 6, 2026 – (ACN Newswire) – On February 6, Distinct Healthcare Holdings Limited (“Distinct Healthcare” or the “Company”, Stock Code: 2677.HK), a leading player in China’s mid-to-high-end consumer healthcare services market, was successfully listed on the main board of the Hong Kong Stock Exchange, emerging as a high-quality and rare private healthcare gem in the Hong Kong stock market. This marks the beginning of a new chapter in the Company’s scaled and high-quality development.
On its debut, Distinct Healthcare delivered a standout debut, opening sharply higher at HK$81 per share (a 35.23% premium to the offer price), well above the offer price—an indication of strong capital market recognition of the Company’s growth potential. The active trading and high investor enthusiasm further corroborate the market’s firm confidence in the consumer healthcare services sector and the Company’s core value.
Possessing a Large Customer Base with Continuously Improving Profitability
As the third-largest provider of private mid- to high-end healthcare service in China, Distinct Healthcare has always adhered to its patient-oriented core principle, placing patient well-being at the forefront. This approach has enabled the Company to gradually build a large and high-quality patient base, leading the industry in both user scale and return rate.
From 2022 up to the eight months ending 31 August 2025, the total number of patients served by its healthcare institutions in China rose from 162,393 to 212,180, and the total number of paid patient visits of its healthcare service institutions and tele-healthcare service platform grew from 529,829 to 642,132.
Patient loyalty has continued to rise, with the patient return rate steadily climbing. In 2022, 2023, 2024 and the eight months ended 31 August 2025, the patient return rates reached 75.7%, 78.2%, 80.0% and 82.7%, respectively. This robust growth is a strong testament to the market and patients’ high recognition of Distinct Healthcare’s service quality.
Leveraging its large and high-quality customer base and the advantages of its standardized medical services, Distinct Healthcare has achieved steady business growth “without relying on medical insurance subsidies or excessive marketing expenditure”. Financial data shows the Company’s total revenue increased steadily from RMB473 million in 2022 to RMB959 million in 2024, doubling its revenue in two years and achieving a compound annual growth rate (CAGR) of 42.3%, demonstrating strong growth momentum.
In terms of profitability, the Company achieved a critical milestone by turning profitable in 2024, with an adjusted net profit of RMB10.7 million. This represents a qualitative leap from scale-driven growth to profitability-driven growth.
Strong Line-up of Cornerstone Investors and Clear Strategic Plan Support High-Quality Development
Distinct Healthcare has attracted a strong roster of cornerstone investors in this IPO, including Health Vision, Kingmed Diagnostics, Mininglamp Technology, and Galaxy Dynasty. Together, they subscribed for a total of approximately HK$90.7876 million. The active participation of these renowned, high-quality institutional investors fully reflects their high recognition of Distinct Healthcare’s core competitiveness, business model, and future development prospects,